MRNS Deadline: MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - The Rosen Law Firm is investigating allegations that Marinus Pharmaceuticals, Inc. misled investors regarding its business operations, particularly related to the RAISE trial and its implications for the company's future [1][6]. Group 1: Class Action Lawsuit - A class action lawsuit has been filed on behalf of all individuals and entities that purchased securities of Marinus Pharmaceuticals between March 17, 2021, and May 7, 2024 [5]. - Shareholders wishing to serve as lead plaintiff must file motions with the court by August 5, 2024 [5][7]. - The lawsuit claims that Marinus made materially false and misleading statements about its business operations and the risks associated with the RAISE trial [6]. Group 2: Impact of RAISE Trial - An article published by Fierce Biotech on May 8, 2024, highlighted the consequences of failing to meet early stopping criteria in the RAISE trial, which led to a decline in Marinus Pharmaceuticals' stock price [4]. - The lawsuit alleges that the company understated the risks of failing to meet these criteria and did not disclose the potential impact on the separate Phase 3 RAISE II trial [6].